Source link : https://www.newshealth.biz/health-news/fda-panel-supports-more-clarity-in-nsclc-perioperative-immunotherapy-trials/
The FDA should require clinical trials in perioperative therapy for non-small cell lung cancer (NSCLC) to address the individual contributions of neoadjuvant and adjuvant treatment to outcomes, an advisory committee unanimously recommended. By an 11-0 vote, the Oncologic Drugs Advisory Committee (ODAC) agreed with the FDA staff position that standard two-arm trials do not adequately […]
Author : News Health
Publish date : 2024-07-25 21:28:42
Copyright for syndicated content belongs to the linked Source.
Categories